Abbott to Invest More in R&D in Emerging Markets, CEO Says

Abbott Laboratories (ABT) plans to invest more in research and development in emerging markets, Chief Executive Officer Miles White said. He spoke at a Financial Times pharmaceutical industry conference in London.

To contact the reporter on this story: Makiko Kitamura in London at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.